Precision Medicine Division
Transforming patient outcomes through genomic intelligence, AI-driven diagnostics, and personalized therapeutic pathways. Moving healthcare from reactive to predictive.
Next-Generation Personalized Care
Leveraging cross-divisional AI, quantum computing, and global clinical data to deliver treatments tailored to individual biological profiles.
Aevum Zenth's Precision Medicine Division operates at the convergence of genomics, machine learning, and clinical pharmacology. By integrating real-world evidence with longitudinal patient data, we identify biomarkers, predict therapeutic responses, and accelerate the development of targeted interventions.
Our infrastructure processes multi-omics data streams across oncology, rare diseases, autoimmune disorders, and neurodegenerative conditions, enabling clinicians to move beyond trial-and-error prescribing.
- End-to-end genomic sequencing & variant interpretation
- AI-powered drug repurposing & target discovery
- Real-time pharmacogenomic dosing algorithms
- Secure, federated clinical data networks
Integrated Diagnostic & Therapeutic Ecosystem
Proprietary platforms engineered for clinical scale, regulatory compliance, and cross-institutional interoperability.
ZenthGenomics™
High-throughput whole genome & exome sequencing with AI-driven clinical variant classification. Delivers actionable reports within 72 hours.
NGS / WGS CLIA CertifiedOncoMatch™
Oncology-focused biomarker profiling matching tumor molecular signatures to targeted therapies, immunotherapies, and clinical trials.
Oncology Trial MatchingNeuroSeq Initiative
Multi-modal mapping of neurodegenerative pathways using proteomics, transcriptomics, and longitudinal cognitive assessments.
Neurology LongitudinalPharmacogenomics Engine
Predictive modeling of drug metabolism, efficacy, and adverse event risk based on CYP450 variants and polygenic risk scores.
Precision Dosing AI/MLTherapeutic Development & Research
From bench to bedside: advancing targeted interventions across high-burden disease categories.
| Program | Indication | Mechanism | Phase | Status |
|---|---|---|---|---|
| AZP-014 | Non-Small Cell Lung Cancer | EGFR/ALK Dual Inhibitor | Phase III | Active Enrollment |
| AZP-022 | Rare Genetic Ataxia | Gene Silencing / ASO | Phase II | Dose Optimization |
| AZP-009 | Autoimmune Rheumatology | Checkpoint Modulation | Phase I | Safety Monitoring |
| ZenthCardio™ | Familial Hypercholesterolemia | siRNA Lipid Lowering | Commercial | Global Distribution |
Enterprise-Grade Security & Ethics
Patient data sovereignty, regulatory alignment, and transparent AI governance across all precision medicine workflows.
HIPAA & GDPR Compliant
End-to-end encryption, role-based access, and audit logging for all PHI/clinical datasets.
Federated Learning
Model training across institutions without centralized patient data sharing.
FDA/EMA Alignment
SaMD validation pathways, real-world evidence frameworks, and GxP compliance.
Ethical AI Governance
Bias mitigation, explainable ML outputs, and independent oversight committees.
Advance Your Clinical Research
Whether you're a hospital network, biotech partner, or academic institution, discover how Aevum Zenth's precision medicine infrastructure can accelerate your pipeline and improve patient stratification.